:: Doloxe :: Daily News

$U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma$

10/25/2022

U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

10/24/2022

RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease

10/23/2022

WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities

04/06/2021

HUYABIO International/Submits/HBI-8000 Monotherapy for Peripheral/T-cell Lymphoma for Regulatory Approval in Japan

04/05/2021

Bioniz Therapeutics Receives Orphan Drug Designation from the European Commission for BNZ-1 for Treatment of Cutaneous T-Cell Lymphoma

07/29/2020

AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention

07/29/2020

Novartis receives Piqray approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation

05/08/2020

AbbVie Completes Transformative Acquisition of Allergan

05/08/2020

CytoDyn Clarifies Status of Biologics License Application

05/07/2020

Gilead Announces Approval of Veklury (remdesivir) in Japan for Patients With Severe COVID-19

02/06/2020

Kleo Pharmaceuticals Receives IND Authorization to Proceed from FDA for its Multiple Myeloma Therapeutic

02/06/2020

Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy

01/03/2020

I-Mab Biopharma/Announces/Dosing of First Patient in a Pivotal Phase 2 Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

01/03/2020

Orphazyme Reports Positive Arimoclomol Data From Open-Label Phase 2/3 Extension In Niemann-Pick Disease Type C

01/02/2020

BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment

01/02/2020

DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis

12/30/2019

Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer

12/23/2019

Sosei Heptares Announces the First Phase I Clinical Start From Its Multi-target Drug Discovery Collaboration With Pfizer

12/23/2019

Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint

12/23/2019

Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND

12/23/2019

FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease

12/18/2019

Mycovia Pharmaceuticals Completes Enrollment in its Third Phase 3 Clinical Trial for VT-1161 (ultraVIOLET) in Patients with Recurrent Vulvovaginal Candidiasis

12/16/2019

BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide

12/11/2019

Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

12/10/2019

Daiichi Sankyo Initiates Pivotal Phase 2 Trial in Japan with Valemetostat in Patients with Adult T-Cell Leukemia-Lymphoma